Title: Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and
immune response in pancreatic cancer
Version: 2 Date: 25 Jul 2022
Reviewer's report:
The authors have analyzed interesting RNA-markers’ association to survival in pancreatic cancer
patients.
In the Abstract the shortenings should be explained (e.g. TCGA-PAAD cohort).
There were 366 pancreatic cancer patients mentioned in the abstract. In the methods section it is
mentine that there were 176 patients with pancreatic adenocarcinoma and 90 validation patient
group. 100 patients are missing.
Pancreatic adenocarcinoma includes several differen kinds of adenocarcinomas, ductal adenoca
(PDAC), IPMN-based adenoca, mucinous adenoca, squamous type adenoca etc. PDAC
comprices almost 90% of them. All these different types have different prognosis and may
explain the results. It would be interesting to see analysis of the PDACs only.
Title: Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and
immune response in pancreatic cancer
Version: 2 Date: 25 Jul 2022
Reviewer's report:
The authors have analyzed interesting RNA-markers’ association to survival in pancreatic cancer
patients.
In the Abstract the shortenings should be explained (e.g. TCGA-PAAD cohort).
There were 366 pancreatic cancer patients mentioned in the abstract. In the methods section it is
mentine that there were 176 patients with pancreatic adenocarcinoma and 90 validation patient
group. 100 patients are missing.
Pancreatic adenocarcinoma includes several differen kinds of adenocarcinomas, ductal adenoca
(PDAC), IPMN-based adenoca, mucinous adenoca, squamous type adenoca etc. PDAC
comprices almost 90% of them. All these different types have different prognosis and may
explain the results. It would be interesting to see analysis of the PDACs only.
Please review this paper.
user
Title: Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and
immune response in pancreatic cancer
Version: 2 Date: 25 Jul 2022
Reviewer's report:
The authors have analyzed interesting RNA-markers’ association to survival in pancreatic cancer
patients.
In the Abstract the shortenings should be explained (e.g. TCGA-PAAD cohort).
There were 366 pancreatic cancer patients mentioned in the abstract. In the methods section it is
mentine that there were 176 patients with pancreatic adenocarcinoma and 90 validation patient
group. 100 patients are missing.
Pancreatic adenocarcinoma includes several differen kinds of adenocarcinomas, ductal adenoca
(PDAC), IPMN-based adenoca, mucinous adenoca, squamous type adenoca etc. PDAC
comprices almost 90% of them. All these different types have different prognosis and may
explain the results. It would be interesting to see analysis of the PDACs only.
assistant